SOUTH
SAN FRANCISCO, Calif., Aug. 1, 2023
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a
precision medicine oncology company committed to the discovery and
development of targeted therapeutics, announced its participation
in an upcoming investor relations event.
BTIG Virtual Biotechnology Conference 2023
Tuesday, August 8th, 2023
at 3:00 PM ET
- Fireside chat with Yujiro S.
Hata, Chief Executive Officer, hosted by Justin Zelin, Director, Biotechnology Research
Analyst
A live audio webcast of the conference event will be available
through the conference host.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's recent
Annual Report on Form 10-K filed on May 9,
2023 and any current and periodic reports filed with the
U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Paul Stone
Chief Financial Officer
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-august-2023-investor-relations-event-301889728.html
SOURCE IDEAYA Biosciences, Inc.